Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration

DOĞAN, Mustafa; DIVARCI, Safiye YİĞİT; IRGAT, Saadet Gültekin; ÖZÇURA, Fatih

doi:10.37845/ret.vit.2021.30.38

Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration

Saadet GÜLTEKİN IRGAT, (Kütahya Sağlık Bilimleri Üniversitesi, Evliya Çelebi Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Anabilim Dalı, Kütahya, Türkiye)

Safiye YİĞİT DIVARCI, (Kütahya Sağlık Bilimleri Üniversitesi, Evliya Çelebi Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Anabilim Dalı, Kütahya, Türkiye)

Mustafa DOĞAN, (Afyonkarahisar Sağlık Bilimleri Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Afyon, Türkiye)

Fatih ÖZÇURA (Kütahya Sağlık Bilimleri Üniversitesi, Evliya Çelebi Eğitim ve Araştırma Hastanesi, Göz Hastalıkları Anabilim Dalı, Kütahya, Türkiye)

Retina-Vitreus

4 0

Yıl: 2021 Cilt: 30 Sayı: 2 Sayfa Aralığı: 212 - 222 Metin Dili: İngilizce DOI: 10.37845/ret.vit.2021.30.38 İndeks Tarihi: 18-05-2022

Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration

Öz:

Age-related macular degeneration (AMD), which can result in central vision loss, is among the leading causes of blindness world wide. The beginning of the anti-vascular endothelial growth factor (anti-VEGF) era has revolutionized the treatment of AMD. The efficacy of anti-VEGFs (bevacizumab, ranibizumab and aflibercept) has been proven in important clinical studies such as ANCHOR, MARINA and VIEW, leading to the widespread use of these agents in the treatment of AMD. This review focuses on important clinical studies using 3 anti-VEGF agents and their link with real-world evidence including data point specific to our country. Also, the efficacy of anti-VEGF agents and real-life treatment regimens will be reviewed. New treatments under development in the search for the ideal agent for AMD treatment will also be discussed.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Bibliyografik

1. WHO. Causes of blindness and visual impairment. Available [Online] at: http://www.who.int/blindness/causes/en/ Accessed on 4 October 2018.
2. Stewart MW. Intravitreal Anti Vascular Endothelial Growth Factor Agents in The Management of Retinal Diseases: An Audit. Mayo Clin Proc. 2012;87:77-88.
3. Vingerling JR, Dielemans I, Hoffmann A at al. The prevalence of age-related maculopathy in the Rotterdam study. Ophtalmology. 1995;12:205-10
4. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health.2014;2:106-16.
5. McLeod DS, Taomoto M, Otsuji T, et al. Quantifying changes in RPE and choroidal vasculature in eyes with agerelated maculardegeneration. Invest Ophthalmol Vis Sci. 2002; 43: 1986-93.
6. Gaengel K, Genove G, Armulik A, et al. Endothelial-mural cellsignaling in vascular development and angiogenesis. Arterioscler Thromb VascBiol. 2009; 29: 630-8.
7. Miao H, Tao Y, Li XX. In flammatory cytokines in aqueous humor of patientswith choroidal neovascularization. Mol Vis. 2012; 18: 574-80.
8. Martin DF, Maguire MG, Ying GS, et al; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-908.
9. Heier JS, Brown DM, Chong V, et al. Intravitreal a flibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-48.
10. Wykoff CC, Croft DE, Brown DM, et al; TREX-YBMD Study Group. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-YBMD 1-Year Results. Ophthalmology. 2015;122:2514-22.
11. Rofagha S, Bhisitkul RB, Boyer DS, et al; SEVENUP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292-9
12. Presta LG, Chen H, O’Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-9.
13. Gragoudas ES, Adamis AP, Cunningham Jr. ET, et al: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-16
14. Brown DM, Michels M, Kaiser PK,. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116: 57-65, e55.
15. Rosenfeld PJ, Brown DM, Heier JS, et al . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
16. Tah V, Orlans HO, Hyer J, et al. Anti-VEGF therapy and the retina: An update. J Ophthalmol. 2015; 2015:627-74
17. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67.
18. Abraham P, Yue H, Wilson L. Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age- Related Macular Degeneration: PIER Study Year 2. Am J Ophthalmol 2010;150:315-24.
19. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Ef ficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118:831-9.
20. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitrealaflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193-201
21. Ogura Y, Terasaki H, Gomi F, et al. Ef ficacy and safety of intravitrealaflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol. 2015;99:92-7.
22. Inoue M, Yamane S, Sato S, et al. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration. Am J Ophthalmol. 2016;169:95-103.
23. Holz FG, Amoaku W, Donate J, et al. Safety and ef ficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study. Ophthalmology 2011;118:663-71.
24. Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2014;121:2181-92
25. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfovealneovascular age-related macular degeneration. Ophthalmology. 2013;120:1046-56.
26. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117:2134-40.
27. DeCroos FC, Reed D, Adam MK, et al.Treat-and-extend therapy using a flibercept for neovascular age-related macular degeneration: a prospective clinical trial. Am J Ophthalmol. 2017;180:142-150.
28. Ozkaya A, Alkin Z, Togac M, et al. Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience. Korean J Ophthalmol. 2017;31:424-30.
29. Holz FG, Bandello F, Gillies M, et al.Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular YBMD registries within the LUMINOUS programme. Br J Ophthalmol. 2013;97:1161-7.
30. Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220-26.
31. Jain N, Yadav NK, Jayadev C, et al. The ARMOUR Study: Anti-VEGF in Neovascular YBMD--Our Understanding in a Real-World Indian Setting. Asia Pac J Ophthalmol (Phila). 2017;6:488-92.
32. Özkaya A, Karaba ş L, Alagöz C, et al. Real-world outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in Turkey: a multicenter retrospective study, Bosphorus retina study group report No: 1. Turk J Ophthalmol. 2018;48:232-7.
33. Erden B, Bölükba şı S, Özkaya A, et al. Comparison of two different treatment regimens' efficacy in neovascular age-related macular degeneration in Turkish population—based on real life data-Bosphorus RWE Study GroupInt J Ophthalmol. 2020; 13: 104-11
34. Murat Karaçorlu, Mümin Hocaoğlu, Serra Arf, et al. Risk-based Algorithm-guided Treatment Protocol for the Management of Neovascular Age-related Macular Degeneration Turk J Ophthalmol. 2019;49: 258-69
35. Lotery A, Griner R, Ferreira A, et al. Real-world visual acuity outcomes between ranibizumab and a flibercept in treatment of neovascular YBMD in a large US data set. Eye. 2017;31:1697-706.
36. Gillies MC, Nguyen V, Daien V, et al. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Ophthalmology. 2016;123:2545-53.
37. Vorum H, Olesen TK, Zinck J, et al. Real world evidence of use of anti-VEGF therapy in Denmark. Curr Med Res Opin. 2016;32:1943-50.
38. Rao P, Lum F, Wood K, et al. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry. Ophthalmology. 2018;125:522-8.
39. Hussain RM, Ciulla TA. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Expert OpinEmerg Drugs. 2017;22:235-46.
40. Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age- Related Macular Degeneration. Ophthalmology. 2020 Jun 20:S0161-6420(20)30570-4. doi: 10.1016/j.ophtha.2020.06.028. Online ahead of print.
41. Esmaili DD and Boyer DS. Recent advances in understanding and managing retinal vein occlusions. F1000Research. 2018;7.
42. Zhang Y, Han Q, Ru Y,et al. Anti-VEGF treatment for myopic choroid neovascularlization: From molecular characterization to update on clinical application. Drug Design Development and Therapy 2015;9:3413-21.
43. Matri LE, Chebil A, Kort F. Current and emerging treatment options for myopic choroidal neovascularization. ClinOphthalmol. 2015;9:733-44.
44. Das A, McGuire P, Monickaraj F. Novel pharmacotherapies in diabetic retinopathy: Current status and what’s in the horizon? Indian J Ophthalmol. 2016;64:4-13.
45. Sabbadini RA. Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br J Pharmacol. 2011; 162: 1225-38.
46. Nussenblatt RB, Byrnes G, Sen HN, Yeh S, Faia L, Meyerle C, et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina. 2010; 30: 1579-87.
47. Finger PT, Gelman YP, Berson AM, et al. Palladium-103 plaque radiation therapy for macular degeneration: results of a 7 year study. Br J Ophthalmol 2003; 87: 1497-503.
48. Gertner M, Chell E, Pan KH, et al. Stereotactic targeting and dose veri fication for age-related macular degeneration. Med Phys. 2010; 37(2): 600-6.
49. Silva RA, Moshfeghi AA, Kaiser PK, et al. Radiation treatment for age-related macular degeneration. Semin Ophthalmol. 2011; 26: 121-30.
50. Jackson TL, Dugel PU, Bebchuk JD, et al. CABERNET Study Group. Epimacular brachytherapy for neovascular agerelated macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. Ophthalmology. 2013; 120: 1597-603.

APA	IRGAT S, DIVARCI S, DOĞAN M, ÖZÇURA F (2021). Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration. , 212 - 222. 10.37845/ret.vit.2021.30.38
Chicago	IRGAT Saadet Gültekin,DIVARCI Safiye YİĞİT,DOĞAN Mustafa,ÖZÇURA Fatih Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration. (2021): 212 - 222. 10.37845/ret.vit.2021.30.38
MLA	IRGAT Saadet Gültekin,DIVARCI Safiye YİĞİT,DOĞAN Mustafa,ÖZÇURA Fatih Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration. , 2021, ss.212 - 222. 10.37845/ret.vit.2021.30.38
AMA	IRGAT S,DIVARCI S,DOĞAN M,ÖZÇURA F Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration. . 2021; 212 - 222. 10.37845/ret.vit.2021.30.38
Vancouver	IRGAT S,DIVARCI S,DOĞAN M,ÖZÇURA F Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration. . 2021; 212 - 222. 10.37845/ret.vit.2021.30.38
IEEE	IRGAT S,DIVARCI S,DOĞAN M,ÖZÇURA F "Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration." , ss.212 - 222, 2021. 10.37845/ret.vit.2021.30.38
ISNAD	IRGAT, Saadet Gültekin vd. "Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration". (2021), 212-222. https://doi.org/10.37845/ret.vit.2021.30.38

APA	IRGAT S, DIVARCI S, DOĞAN M, ÖZÇURA F (2021). Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration. Retina-Vitreus, 30(2), 212 - 222. 10.37845/ret.vit.2021.30.38
Chicago	IRGAT Saadet Gültekin,DIVARCI Safiye YİĞİT,DOĞAN Mustafa,ÖZÇURA Fatih Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration. Retina-Vitreus 30, no.2 (2021): 212 - 222. 10.37845/ret.vit.2021.30.38
MLA	IRGAT Saadet Gültekin,DIVARCI Safiye YİĞİT,DOĞAN Mustafa,ÖZÇURA Fatih Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration. Retina-Vitreus, vol.30, no.2, 2021, ss.212 - 222. 10.37845/ret.vit.2021.30.38
AMA	IRGAT S,DIVARCI S,DOĞAN M,ÖZÇURA F Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration. Retina-Vitreus. 2021; 30(2): 212 - 222. 10.37845/ret.vit.2021.30.38
Vancouver	IRGAT S,DIVARCI S,DOĞAN M,ÖZÇURA F Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration. Retina-Vitreus. 2021; 30(2): 212 - 222. 10.37845/ret.vit.2021.30.38
IEEE	IRGAT S,DIVARCI S,DOĞAN M,ÖZÇURA F "Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration." Retina-Vitreus, 30, ss.212 - 222, 2021. 10.37845/ret.vit.2021.30.38
ISNAD	IRGAT, Saadet Gültekin vd. "Overview of Anti-VEGF Treatment Regimens and New Agents in Age-Related Macular Degeneration". Retina-Vitreus 30/2 (2021), 212-222. https://doi.org/10.37845/ret.vit.2021.30.38